FBnTP Imaging of Breast Cancer

• Status: Suspended
• Trial end date: 2021-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

Our preclinical studies suggest the capacity of the positron emission tomography imaging agent 18F-fluorobenzyl triphenyl phosphonium (FBnTP) to detects early-stage small breast tumors (e.g., DCIS), and differentiates benign from malignant masses with better accuracy than that obtained by existing breast imaging tools.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Criteria

Inclusion Criteria:

• Female patients with newly-diagnosed invasive and/or intraductal breast cancer detected by core needle or vacuum-assisted biopsy (i.e., index cancer)

• Age > 25 Ability and willingness to sign informed consent prior to any study procedure.

• Positive indication of disease on mammogram or MRI scan.

• Candidate for breast cancer surgery on the basis of recommendation of a breast cancer surgeon.

• Ability to undergo up to 90 minutes of PEM imaging.

Exclusion Criteria:

• Any active or chronic illness that, in the opinion of the investigators, would make the study unsafe or limit compliance with study procedures.

• Past or present history of active substance abuse (drug or alcohol).

• Inability to tolerate venous access.

• Pregnant females are excluded from this study. All females of child-bearing potential will undergo a serum pregnancy test within 48 hours prior to FBnTP administration.